ArticleClinics (Sao Paulo, Brazil)2024

Larotrectinib versus infigratinib for adult patients with both glioma and tyrosine kinase alterations after failure of initial therapies: Efficacy and safety analysis.

Yufang Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.